STOCKHOLM, SWEDEN, December 4, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company PharmNovo’s drug candidate PN6047 will be evaluated as a potential treatment for opioid withdrawal syndrome. The U.S. National Institute of Drug Abuse, NIDA, has funded a collaboration project to investigate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), in a preclinical model.

瑞典斯德哥尔摩，2023年12月4日。Karolinska Development AB（纳斯达克股票代码：KDEV）今天宣布其投资组合公司PharmNovo的候选药物PN6047将被评估为阿片类药物戒断综合征的潜在治疗方法。美国国家药物滥用研究所NIDA资助了一个合作项目，用于在临床前模型中研究新型高选择性δ阿片受体激动剂（DORA）PN6047。

NIDA is a federal scientific research institute with a mission to advance science on the causes and consequences of drug use and addiction. The interest in PN6047 reflects NIDA’s efforts to find effective treatments for opioid withdrawal to tackle the persistent challenge of opioid addiction which is a significant public health concern in the U.S.

NIDA是一个联邦科学研究机构，其使命是推进关于吸毒和成瘾的原因和后果的科学。对PN6047的兴趣反映了NIDA努力寻找有效的阿片类药物戒断治疗方法，以应对阿片类药物成瘾的持续挑战，这是美国重大的公共卫生问题。

and globally. PN6047 is a highly selective Delta Opioid Receptor Agonist (DORA) developed as a potential treatment of neuropathic pain and opioid withdrawal with a completely new approach. PN6047 selectively targets the delta opioid receptor without affecting the mu-opioid receptor often associated with high risks of addiction and side effects.

和全球。PN6047是一种高度选择性的δ阿片受体激动剂（DORA），可通过全新的方法开发为神经性疼痛和阿片类药物戒断的潜在治疗方法。PN6047选择性靶向δ阿片受体而不影响通常与成瘾和副作用的高风险相关的μ阿片受体。

Encouraged by these findings, NIDA will fund a collaboration between PharmNovo and Professor Amynah Pradhan at Washington University, and Emily Jutkiewicz at the University of Michigan to conduct tests in preclinical models of opioid withdrawal syndrome and to explore its differences from conventional opioids.

受到这些发现的鼓舞，NIDA将资助PharmNovo与华盛顿大学的Amynah Pradhan教授和密歇根大学的Emily Jutkiewicz之间的合作，在阿片类药物戒断综合征的临床前模型中进行测试，并探讨其与传统阿片类药物的差异。

”The interest from NIDA in PharmNovo’s drug candidate PN6047 highlights its potential as a new treatment of nerve pain that makes it possible to avoid the addiction problem associated with other pain therapies. Opioid addiction is a major problem globally, and we are glad that our strong confidence in this unique drug candidate is supported by such a .

“NIDA对PharmNovo候选药物PN6047的兴趣突出了其作为神经疼痛新疗法的潜力，从而可以避免与其他疼痛疗法相关的成瘾问题。阿片类药物成瘾是全球的一个主要问题，我们很高兴我们对这种独特的候选药物的强烈信心得到了这样的支持。

Attachment

附件

KD PharmNovo NIDA fund eng

KD PharmNovo NIDA fund eng